Cargando…
Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
BACKGROUND: A previous cohort study indicated that atazanavir (ATV), a protease inhibitor used for HIV treatment, is not associated with an increased risk of cardiovascular (CV) events. The objective of this study was to compare the risk of CV events among antiretroviral-naïve patients initiating AT...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028993/ https://www.ncbi.nlm.nih.gov/pubmed/27643691 http://dx.doi.org/10.1186/s12879-016-1827-1 |